2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.
How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population.
The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular co
NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.
Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4.
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Lancet Respiratory Medicine has reported the results of the COLCORONA trial, showing that in patients with PCR-confirmed COVID-19 infection, colchicine led to a significantly lower rate of death or hospital admission from COVID.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
Dr. Antoni Chan @synovialjoints ( View Tweet )
